None
Conditions
Interventions
Experimental group:Simultaneous treatment of persistent atrial fibrillation during cardiac surgery
Sponsors
Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age range: 18 - 80 years old (inclusive of 18 and 80). Gender is not restricted. 2.Planning to undergo cardiac surgery (including valve replacement or repair surgery, coronary artery bypass surgery, etc.); 3.Combination of persistent atrial fibrillation (Definition of persistent atrial fibrillation: The atrial fibrillation episode cannot terminate on its own, lasts for more than 7 days, and can be terminated through intervention); 4.Being able to understand the purpose of this trial, voluntarily participating in this study and signing the informed consent form, and willing to complete the follow-up as per the protocol requirements.
Exclusion criteria
Exclusion criteria: 1. Previously underwent cardiac surgical maze procedure; 2. Long R-R interval; 3. Requires urgent cardiac surgery (such as cardiogenic shock); 4. Requires intra-aortic balloon counterpulsation or intravenous cardiac stimulants before surgery; 5. Left ventricular ejection fraction (LVEF) = 6 cm; 7. Cardiac function classification (NYHA) IV grade; 8. Has one or more pulmonary vein stents, or has an implanted cardiac cardioverter defibrillator, pacemaker or any other implanted electronic device; 9. Patients with acute systemic active infection who, according to the investigator's judgment, cannot undergo surgical treatment; 10. Anticoagulation contraindications and those with a history of abnormal blood clotting or bleeding or a significant bleeding tendency who cannot undergo surgery or are undergoing hemodialysis for renal failure patients; 11. Patients who have experienced acute myocardial infarction within 6 weeks; 12. Patients who have experienced stroke (except for lacunar infarction) or transient ischemic attack within 6 months; 13. Patients with obvious surgical contraindications or an expected survival period < 1 year; 14. Subjects who are pregnant or breastfeeding or who cannot be prevented from contraception during the trial and are female with reproductive planning issues; 15. Subjects who are currently participating in another clinical study that has not yet completed the main endpoint; 16. Other situations that the investigator deems inappropriate for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of major adverse events (MAE) related to the equipment or the surgery within one month after the operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| The effective rate of treatment 6 months after the surgery;Incidence of adverse events and serious adverse events;The rate of anti-arrhythmic re-intervention 6 months after the surgery; | — |
Countries
China
Contacts
Public ContactLiu Jian
Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)
Outcome results
None listed